title: [Adverse effects of bisphosphonates].
abstract: Aminobisphosphonates are drugs that have been used successfully in the treatment of osteoporosis for more than 20 years. Although main registry studies found a scarcity of relevant adverse events, in recent years and as a result of pharmacovigilance, different complications have been reported, some potentially serious. This has raised questions on the safety of these drugs, especially in high doses, like those used in oncology and long-term treatment, as needed in patients with osteoporosis. In this review, based on the analysis of relevant scientific evidence from clinical trials, case series, cohort studies and databases published to date, we summarize the clinical and epidemiological characteristics of the adverse effects of these drugs.
authors.affiliation: Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, España. arboleya@ser.es
authors.forename: Luis
authors.initials: L
authors.lastname: Arboleya
authors.forename: Mercedes
authors.initials: M
authors.lastname: Alperi
authors.forename: Sara
authors.initials: S
authors.lastname: Alonso
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D050723:Fractures, Bone / Q000139:chemically induced; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates